Two licensing deals on the same day show that radiopharmaceuticals is still an active area.

A stacked user fee goal lineup sets the stage for market showdowns in primary biliary cholangitis and IgA nephropathy, the first psychedelic approval decision, and lots of targeted cancer therapies.

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Biotechs have had a difficult time raising cash through flotations over the past quarter, with one stepping away altogether.